How can we, humans, look at our relationship to nature differently? In season three of Going Wild, on top of stories about animals, we invite you to journey through the entire ecological web — from the tiniest of life forms to apex predators — alongside the scientists, activists and adventurers who study it. Wildlife biologist and host Dr. Rae Wynn-Grant has been studying wild animals in their natural habitats all over the world for years. Our award-winning podcast takes you inside the hidde ...
…
continue reading
Content provided by Sano Genetics. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sano Genetics or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
EP 121: Breakthroughs and insights in ALS research with Dr. Michael Benatar
MP3•Episode home
Manage episode 399897232 series 2631947
Content provided by Sano Genetics. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sano Genetics or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Summary:
0:00 Introduction
0:50 Reflections from the 34th International Symposium on ALS/MND in Basel
1:50 Michael’s professional journey, initial challenges he encountered, and how the field of neurology has evolved over the years
3:10 An introduction to the ALS landscape, including its presentation, the genes involved, and potential treatment options
4:50 A framework for the stages of ALS, from being at risk to phenotypic conversion, and ultimately to the manifestation of disease symptoms.
8:00 The ALS-FTD axis and a broader perspective on the spectrum of neurodegenerative diseases
10:50 Potential genetic modifiers of ALS, including C9orf72 and SOD1, and future research
11:55 A refined approach to identifying precise biomarkers for ALS
15:15 The potential of phenotypic reversal in adult ALS patients undergoing ASO therapy
17:50 An introduction to the global ATLAS trial and applying therapies to pre-symptomatic populations
21:30 The broadening the ATLAS trial to include other genetic forms of ALS
23:20 The identification of additional biomarkers for ALS that may allow for earlier diagnosis or provide more insights into ALS
25:50 Holistic care for the ALS community, including patients and their loved ones
30:40 The evolving picture of genetics and ALS, beyond known monogenic risk factors
36:00 Michael’s 2016 publication in Neurology: Presymptomatic ALS genetic counseling and testing: Experience and recommendations
37:45 The need for legal protection from insurance policy changes given predictive biomarker results
38:30 Looking ahead 10-20 years: What will prove transformative in the next decade for ALS research and treatment?
41:30 Exploration of a generalized treatment for neurodegenerative diseases and the potential to leverage a universally-protective genetic mechanism
42:10 Closing remarks and gratitude for the those working to improve the lives of ALS community
177 episodes
MP3•Episode home
Manage episode 399897232 series 2631947
Content provided by Sano Genetics. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sano Genetics or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Summary:
0:00 Introduction
0:50 Reflections from the 34th International Symposium on ALS/MND in Basel
1:50 Michael’s professional journey, initial challenges he encountered, and how the field of neurology has evolved over the years
3:10 An introduction to the ALS landscape, including its presentation, the genes involved, and potential treatment options
4:50 A framework for the stages of ALS, from being at risk to phenotypic conversion, and ultimately to the manifestation of disease symptoms.
8:00 The ALS-FTD axis and a broader perspective on the spectrum of neurodegenerative diseases
10:50 Potential genetic modifiers of ALS, including C9orf72 and SOD1, and future research
11:55 A refined approach to identifying precise biomarkers for ALS
15:15 The potential of phenotypic reversal in adult ALS patients undergoing ASO therapy
17:50 An introduction to the global ATLAS trial and applying therapies to pre-symptomatic populations
21:30 The broadening the ATLAS trial to include other genetic forms of ALS
23:20 The identification of additional biomarkers for ALS that may allow for earlier diagnosis or provide more insights into ALS
25:50 Holistic care for the ALS community, including patients and their loved ones
30:40 The evolving picture of genetics and ALS, beyond known monogenic risk factors
36:00 Michael’s 2016 publication in Neurology: Presymptomatic ALS genetic counseling and testing: Experience and recommendations
37:45 The need for legal protection from insurance policy changes given predictive biomarker results
38:30 Looking ahead 10-20 years: What will prove transformative in the next decade for ALS research and treatment?
41:30 Exploration of a generalized treatment for neurodegenerative diseases and the potential to leverage a universally-protective genetic mechanism
42:10 Closing remarks and gratitude for the those working to improve the lives of ALS community
177 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.